Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Dijkstra KK"'
Autor:
Puttick C; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.; Cancer Genome Evolution Research Group, Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK., Jones TP; Cancer Genome Evolution Research Group, Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK., Leung MM; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.; Cancer Genome Evolution Research Group, Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK., Galvez-Cancino F; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.; Cancer Immunology Unit, Immune Regulation and Tumour Immunotherapy Laboratory, Research Department of Haematology, University College London Cancer Institute, London, UK.; Immune Regulation and Immune Interactions Group, Centre for Immuno-Oncology, Nuffield Department of Medicine, University of Oxford, Oxford, UK., Liu J; Cancer Immunology Unit, Immune Regulation and Tumour Immunotherapy Laboratory, Research Department of Haematology, University College London Cancer Institute, London, UK., Varas-Godoy M; Cancer Cell Biology Laboratory, Centro de Biología Celular y Biomedicina (CEBICEM), Facultad de Medicina y Ciencia, Universidad San Sebastián, Santiago, Chile.; Centro Ciencia & Vida, Fundación Ciencia & Vida, Santiago, Chile., Rowan A; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK., Pich O; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK., Martinez-Ruiz C; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.; Cancer Genome Evolution Research Group, Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK., Bentham R; Cancer Genome Evolution Research Group, Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK., Dijkstra KK; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands., Black JRM; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.; Cancer Genome Evolution Research Group, Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK., Rosenthal R; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK., Kanu N; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK., Litchfield K; Tumour Immunogenomics and Immunosurveillance Laboratory, University College London Cancer Institute, London, UK., Salgado R; Division of Research, Peter MacCallum Cancer Centre, Melbourne, Australia.; Department of Pathology, ZAS Hospitals, Antwerp, Belgium., Moore DA; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.; Department of Cellular Pathology, University College London Hospitals, London, UK., Van Loo P; Cancer Genomics Laboratory, The Francis Crick Institute, London, UK.; Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Jamal-Hanjani M; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.; Cancer Metastasis Laboratory, University College London Cancer Institute, London, UK.; Department of Medical Oncology, University College London Hospitals, London, UK., Quezada SA; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.; Cancer Immunology Unit, Immune Regulation and Tumour Immunotherapy Laboratory, Research Department of Haematology, University College London Cancer Institute, London, UK., Swanton C; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK. charles.swanton@crick.ac.uk.; Cancer Genome Evolution Research Group, Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK. charles.swanton@crick.ac.uk.; Department of Medical Oncology, University College London Hospitals, London, UK. charles.swanton@crick.ac.uk., McGranahan N; Cancer Genome Evolution Research Group, Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK. nicholas.mcgranahan.10@ucl.ac.uk.; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK. nicholas.mcgranahan.10@ucl.ac.uk.
Publikováno v:
Nature genetics [Nat Genet] 2024 Oct; Vol. 56 (10), pp. 2121-2131. Date of Electronic Publication: 2024 Oct 02.
Autor:
Enfield KSS; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, United Kingdom., Colliver E; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, United Kingdom., Lee C; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, United Kingdom., Magness A; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, United Kingdom., Moore DA; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, United Kingdom.; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, United Kingdom.; Department of Cellular Pathology, University College London Hospitals, London, United Kingdom., Sivakumar M; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, United Kingdom., Grigoriadis K; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, United Kingdom.; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, United Kingdom.; Cancer Genome Evolution Research Group, Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, United Kingdom., Pich O; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, United Kingdom., Karasaki T; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, United Kingdom.; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, United Kingdom.; Cancer Metastasis Laboratory, University College London Cancer Institute, London, United Kingdom., Hobson PS; Flow Cytometry, The Francis Crick Institute, London, United Kingdom., Levi D; Flow Cytometry, The Francis Crick Institute, London, United Kingdom., Veeriah S; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, United Kingdom., Puttick C; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, United Kingdom.; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, United Kingdom.; Cancer Genome Evolution Research Group, Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, United Kingdom., Nye EL; Experimental Histopathology, The Francis Crick Institute, London, United Kingdom., Green M; Experimental Histopathology, The Francis Crick Institute, London, United Kingdom., Dijkstra KK; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, United Kingdom., Shimato M; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, United Kingdom., Akarca AU; Department of Cellular Pathology, University College London Hospitals, London, United Kingdom., Marafioti T; Department of Cellular Pathology, University College London Hospitals, London, United Kingdom., Salgado R; Department of Pathology, ZAS Hospitals, Antwerp, Belgium.; Division of Research, Peter MacCallum Cancer Centre, Melbourne, Australia., Hackshaw A; Cancer Research UK and University College London Cancer Trials Centre, London, United Kingdom., Jamal-Hanjani M; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, United Kingdom.; Cancer Metastasis Laboratory, University College London Cancer Institute, London, United Kingdom.; Department of Oncology, University College London Hospitals, London, United Kingdom., van Maldegem F; Oncogene Biology Laboratory, The Francis Crick Institute, London, United Kingdom., McGranahan N; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, United Kingdom.; Cancer Genome Evolution Research Group, Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, United Kingdom., Glass B; PathAI, Inc., Boston, Massachusetts., Pulaski H; PathAI, Inc., Boston, Massachusetts., Walk E; PathAI, Inc., Boston, Massachusetts., Reading JL; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, United Kingdom.; Pre-cancer Immunology Laboratory, University College London Cancer Institute, London, United Kingdom.; Immune Regulation and Tumour Immunotherapy Group, Cancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London, United Kingdom., Quezada SA; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, United Kingdom.; Immune Regulation and Tumour Immunotherapy Group, Cancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London, United Kingdom., Hiley CT; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, United Kingdom.; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, United Kingdom., Downward J; Oncogene Biology Laboratory, The Francis Crick Institute, London, United Kingdom., Sahai E; Tumour Cell Biology Laboratory, The Francis Crick Institute, London, United Kingdom., Swanton C; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, United Kingdom.; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, United Kingdom.; Department of Oncology, University College London Hospitals, London, United Kingdom., Angelova M; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, United Kingdom.
Publikováno v:
Cancer discovery [Cancer Discov] 2024 Jun 03; Vol. 14 (6), pp. 1018-1047.
Autor:
Deben C; Center for Oncological Research (CORE), Integrated Personalized & Precision Oncology Network (IPPON), University of Antwerp, Wilrijk, Belgium. christophe.deben@uantwerpen.be., Boullosa LF; Center for Oncological Research (CORE), Integrated Personalized & Precision Oncology Network (IPPON), University of Antwerp, Wilrijk, Belgium., Fortes FR; Center for Oncological Research (CORE), Integrated Personalized & Precision Oncology Network (IPPON), University of Antwerp, Wilrijk, Belgium., De La Hoz EC; Industrial Vision Lab, University of Antwerp, Wilrijk, Belgium., Le Compte M; Center for Oncological Research (CORE), Integrated Personalized & Precision Oncology Network (IPPON), University of Antwerp, Wilrijk, Belgium., Seghers S; Center for Oncological Research (CORE), Integrated Personalized & Precision Oncology Network (IPPON), University of Antwerp, Wilrijk, Belgium., Peeters M; Center for Oncological Research (CORE), Integrated Personalized & Precision Oncology Network (IPPON), University of Antwerp, Wilrijk, Belgium., Vanlanduit S; Industrial Vision Lab, University of Antwerp, Wilrijk, Belgium., Lin A; Center for Oncological Research (CORE), Integrated Personalized & Precision Oncology Network (IPPON), University of Antwerp, Wilrijk, Belgium.; Plasma Lab for Applications in Sustainability and Medicine ANTwerp (PLASMANT), University of Antwerp, Wilrijk, Belgium., Dijkstra KK; Department of Molecular Oncology and Immunology, the Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands., Van Schil P; Center for Oncological Research (CORE), Integrated Personalized & Precision Oncology Network (IPPON), University of Antwerp, Wilrijk, Belgium.; Department of Thoracic and Vascular Surgery, Antwerp University Hospital, Edegem, Belgium., Hendriks JMH; Center for Oncological Research (CORE), Integrated Personalized & Precision Oncology Network (IPPON), University of Antwerp, Wilrijk, Belgium.; Department of Thoracic and Vascular Surgery, Antwerp University Hospital, Edegem, Belgium., Prenen H; Center for Oncological Research (CORE), Integrated Personalized & Precision Oncology Network (IPPON), University of Antwerp, Wilrijk, Belgium.; Department of Oncology, Multidisciplinary Oncological Center Antwerp, Antwerp University Hospital, Antwerp, Belgium., Roeyen G; Center for Oncological Research (CORE), Integrated Personalized & Precision Oncology Network (IPPON), University of Antwerp, Wilrijk, Belgium.; Department of Hepatobiliary Transplantation and Endocrine Surgery, University Hospital Antwerp (UZA), Edegem, Belgium., Lardon F; Center for Oncological Research (CORE), Integrated Personalized & Precision Oncology Network (IPPON), University of Antwerp, Wilrijk, Belgium., Smits E; Center for Oncological Research (CORE), Integrated Personalized & Precision Oncology Network (IPPON), University of Antwerp, Wilrijk, Belgium.; Center for Cell Therapy and Regenerative Medicine, Antwerp University Hospital, Edegem, Belgium.
Publikováno v:
Journal of experimental & clinical cancer research : CR [J Exp Clin Cancer Res] 2024 Mar 22; Vol. 43 (1), pp. 88. Date of Electronic Publication: 2024 Mar 22.
Autor:
Hughes T; Wellcome Trust/CRUK Gurdon Institute and Department Physiology, Development and Neuroscience, University of Cambridge, Cambridge, United Kingdom., Dijkstra KK; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, Netherlands.; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, United Kingdom., Rawlins EL; Wellcome Trust/CRUK Gurdon Institute and Department Physiology, Development and Neuroscience, University of Cambridge, Cambridge, United Kingdom., Hynds RE; Epithelial Cell Biology in ENT Research (EpiCENTR) Group, Developmental Biology and Cancer Department, Great Ormond Street UCL Institute of Child Health, University College London, London, United Kingdom.; CRUK Lung Cancer Centre of Excellence, UCL Cancer Institute, University College London, London, United Kingdom.; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, United Kingdom.
Publikováno v:
Frontiers in pharmacology [Front Pharmacol] 2023 Jan 13; Vol. 13, pp. 1083017. Date of Electronic Publication: 2023 Jan 13 (Print Publication: 2022).
Autor:
Picco G; Wellcome Sanger Institute, Cambridge, United Kingdom., Cattaneo CM; Department of Molecular Oncology and Immunology, the Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.; Oncode Institute, Amsterdam, the Netherlands., van Vliet EJ; Wellcome Sanger Institute, Cambridge, United Kingdom., Crisafulli G; Candiolo Cancer Institute, FPO-IRCCS, Candiolo (TO), Italy.; Department of Oncology, University of Torino, Candiolo, Italy., Rospo G; Candiolo Cancer Institute, FPO-IRCCS, Candiolo (TO), Italy.; Department of Oncology, University of Torino, Candiolo, Italy., Consonni S; Wellcome Sanger Institute, Cambridge, United Kingdom., Vieira SF; Wellcome Sanger Institute, Cambridge, United Kingdom., Rodríguez IS; Department of Molecular Oncology and Immunology, the Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.; Oncode Institute, Amsterdam, the Netherlands., Cancelliere C; Candiolo Cancer Institute, FPO-IRCCS, Candiolo (TO), Italy., Banerjee R; Wellcome Sanger Institute, Cambridge, United Kingdom., Schipper LJ; Department of Molecular Oncology and Immunology, the Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.; Oncode Institute, Amsterdam, the Netherlands., Oddo D; Candiolo Cancer Institute, FPO-IRCCS, Candiolo (TO), Italy.; Department of Oncology, University of Torino, Candiolo, Italy., Dijkstra KK; Department of Molecular Oncology and Immunology, the Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.; Oncode Institute, Amsterdam, the Netherlands., Cinatl J; Institute for Medical Virology, Goethe-University, Frankfurt am Main, Germany., Michaelis M; School of Biosciences, University of Kent, Canterbury, United Kingdom., Yang F, Di Nicolantonio F; Candiolo Cancer Institute, FPO-IRCCS, Candiolo (TO), Italy.; Department of Oncology, University of Torino, Candiolo, Italy., Sartore-Bianchi A; Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milano, Italy.; Dipartimento di Oncologia ed Emato-Oncologia, Università degli Studi di Milano (La Statale), Milano, Italy., Siena S; Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milano, Italy.; Dipartimento di Oncologia ed Emato-Oncologia, Università degli Studi di Milano (La Statale), Milano, Italy., Arena S; Candiolo Cancer Institute, FPO-IRCCS, Candiolo (TO), Italy.; Department of Oncology, University of Torino, Candiolo, Italy., Voest EE; Department of Molecular Oncology and Immunology, the Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.; Oncode Institute, Amsterdam, the Netherlands., Bardelli A; Candiolo Cancer Institute, FPO-IRCCS, Candiolo (TO), Italy.; Department of Oncology, University of Torino, Candiolo, Italy., Garnett MJ; Wellcome Sanger Institute, Cambridge, United Kingdom. mg12@sanger.ac.uk.
Publikováno v:
Cancer discovery [Cancer Discov] 2021 Aug; Vol. 11 (8), pp. 1923-1937. Date of Electronic Publication: 2021 Apr 09.
Autor:
Ooft SN; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Oncode Institute, Utrecht, The Netherlands., Weeber F; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Oncode Institute, Utrecht, The Netherlands., Schipper L; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Oncode Institute, Utrecht, The Netherlands., Dijkstra KK; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Oncode Institute, Utrecht, The Netherlands., McLean CM; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Oncode Institute, Utrecht, The Netherlands., Kaing S; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Oncode Institute, Utrecht, The Netherlands., van de Haar J; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Oncode Institute, Utrecht, The Netherlands; Department of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Prevoo W; Department of Radiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., van Werkhoven E; Department of Biometrics, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Snaebjornsson P; Department of Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Hoes LR; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Oncode Institute, Utrecht, The Netherlands., Chalabi M; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Oncode Institute, Utrecht, The Netherlands; Department of Gastrointestinal Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., van der Velden D; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Oncode Institute, Utrecht, The Netherlands; Department of Gastrointestinal Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Radiology and Nuclear Medicine, Amsterdam University Medical Center AMC, Amsterdam, The Netherlands., van Leerdam M; Department of Gastrointestinal Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Boot H; Department of Gastrointestinal Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Grootscholten C; Department of Gastrointestinal Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Huitema ADR; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Clinical Pharmacy, University Medical Centre Utrecht, Utrecht, The Netherlands., Bloemendal HJ; Department of Internal Medicine/Oncology, Radboud University Medical Center Nijmegen, Nijmegen, The Netherlands., Cuppen E; Oncode Institute, Utrecht, The Netherlands; Division of Biomedical Genetics, Centre for Molecular Medicine, University Medical Centre Utrecht, Utrecht, The Netherlands; Hartwig Medical Foundation, Amsterdam, The Netherlands., Voest EE; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Oncode Institute, Utrecht, The Netherlands; Department of Gastrointestinal Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. Electronic address: E.voest@nki.nl.
Publikováno v:
ESMO open [ESMO Open] 2021 Jun; Vol. 6 (3), pp. 100103. Date of Electronic Publication: 2021 Apr 19.
Autor:
Dijkstra KK; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, Netherlands.; Oncode Institute, Amsterdam, Netherlands., van den Berg JG; Department of Pathology, Netherlands Cancer Institute, Amsterdam, Netherlands., Weeber F; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, Netherlands.; Oncode Institute, Amsterdam, Netherlands., van de Haar J; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, Netherlands.; Oncode Institute, Amsterdam, Netherlands., Velds A; Central Genomics Facility, Netherlands Cancer Institute, Amsterdam, Netherlands., Kaing S; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, Netherlands.; Oncode Institute, Amsterdam, Netherlands., Peters DDGC; Core Facility Molecular Pathology and Biobanking, Netherlands Cancer Institute, Amsterdam, Netherlands., Eskens FALM; Department of Medical Oncology, Erasmus Medical Center, Rotterdam, Netherlands., de Groot DA; Department of Medical Oncology, University Medical Center Groningen, Groningen, Netherlands., Tesselaar MET; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands., Voest EE; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, Netherlands.; Oncode Institute, Amsterdam, Netherlands.
Publikováno v:
Frontiers in endocrinology [Front Endocrinol (Lausanne)] 2021 Mar 11; Vol. 12, pp. 627819. Date of Electronic Publication: 2021 Mar 11 (Print Publication: 2021).
Autor:
Black JRM; Cancer Genome Evolution Research Group, University College London Cancer Institute, University College London, London, UK., Bailey C; Cancer Evolution and Genome Instability Laboratory, Francis Crick Institute, London NW1 1AT, UK., Przewrocka J; Cancer Evolution and Genome Instability Laboratory, Francis Crick Institute, London NW1 1AT, UK., Dijkstra KK; Cancer Evolution and Genome Instability Laboratory, Francis Crick Institute, London NW1 1AT, UK., Gandhi S; Francis Crick Institute, London, UK., Gamblin S; Francis Crick Institute, London, UK., Barrell S; Francis Crick Institute, London, UK., Swanton C; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, University College London, London, UK; Cancer Evolution and Genome Instability Laboratory, Francis Crick Institute, London NW1 1AT, UK; University College London Hospitals NHS Trust, London, UK. Electronic address: charles.swanton@crick.ac.uk.
Publikováno v:
Lancet (London, England) [Lancet] 2020 Oct 24; Vol. 396 (10259), pp. 1329-1330.
Challenges in Establishing Pure Lung Cancer Organoids Limit Their Utility for Personalized Medicine.
Autor:
Dijkstra KK; Department of Molecular Oncology and Immunology, the Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, 1066 CX Amsterdam, the Netherlands; Oncode Institute, Utrecht, the Netherlands., Monkhorst K; Department of Pathology, the Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, 1066 CX Amsterdam, the Netherlands., Schipper LJ; Department of Molecular Oncology and Immunology, the Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, 1066 CX Amsterdam, the Netherlands; Oncode Institute, Utrecht, the Netherlands., Hartemink KJ; Department of Surgery, the Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, 1066 CX Amsterdam, the Netherlands., Smit EF; Department of Thoracic Oncology, the Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, 1066 CX Amsterdam, the Netherlands., Kaing S; Department of Molecular Oncology and Immunology, the Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, 1066 CX Amsterdam, the Netherlands; Oncode Institute, Utrecht, the Netherlands., de Groot R; Department of Hematopoiesis, Sanquin Research, 1066 CX Amsterdam, the Netherlands; Landsteiner Laboratory, Amsterdam University Medical Center, Location AMC, 1105 AZ Amsterdam, the Netherlands; Oncode Institute, Utrecht, the Netherlands., Wolkers MC; Department of Hematopoiesis, Sanquin Research, 1066 CX Amsterdam, the Netherlands; Landsteiner Laboratory, Amsterdam University Medical Center, Location AMC, 1105 AZ Amsterdam, the Netherlands; Oncode Institute, Utrecht, the Netherlands., Clevers H; Hubrecht Institute, University Medical Center Utrecht, 3584 CT Utrecht, the Netherlands; Princess Maxima Center for Pediatric Oncology, 3584 CS Utrecht, the Netherlands; Oncode Institute, Utrecht, the Netherlands., Cuppen E; Centre for Molecular Medicine, University Medical Centre Utrecht, 3584 CG Utrecht, the Netherlands; Hartwig Medical Foundation, 1098 XH Amsterdam, the Netherlands; Oncode Institute, Utrecht, the Netherlands., Voest EE; Department of Molecular Oncology and Immunology, the Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, 1066 CX Amsterdam, the Netherlands; Oncode Institute, Utrecht, the Netherlands. Electronic address: e.voest@nki.nl.
Publikováno v:
Cell reports [Cell Rep] 2020 May 05; Vol. 31 (5), pp. 107588.
Autor:
Black JRM; Cancer Genome Evolution Research Group, University College London Cancer Institute, University College London, London, UK., Bailey C; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London NW1 1AT, UK., Przewrocka J; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London NW1 1AT, UK., Dijkstra KK; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London NW1 1AT, UK., Swanton C; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London NW1 1AT, UK; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK; University College London Hospitals NHS Trust, London, UK. Electronic address: charles.swanton@crick.ac.uk.
Publikováno v:
Lancet (London, England) [Lancet] 2020 May 02; Vol. 395 (10234), pp. 1418-1420. Date of Electronic Publication: 2020 Apr 16.